Half-year Report

AI SummaryClose X

Solvonis Therapeutics PLC announced its unaudited interim results for the six months ending June 30, 2025. The company's cash and cash equivalents at the period's end totaled £1,719,000, a significant increase from £27,000 in H1 2024. The loss before taxation for the period was £1,621,000, compared to £469,000 in the previous year. The Group's net assets at the period-end were £6,935,000, up from £3,084,000 at the end of 2024, while total assets reached £9,545,000, increasing from £3,203,000 at the end of the prior year. The company completed the acquisition of Awakn Life Sciences, recording an intangible asset of £5,609,237 related to the acquisition. Subsequent to the period end, Solvonis raised £1 million through an equity fundraise.

Disclaimer*

UK 100

Latest directors dealings